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Background: Patients on chronic clopidogrel therapy (CCT) presenting with acute coronary syndrome (ACS) who are undergoing percutaneous 
coronary Intervention (PCI) are subjected to an increase risk due to lack of platelet responsiveness. This study aimed to evaluate whether there is 
additional benefit of reloading with clopidogrel in patients who present with ACS.
Methods: A cohort of 1392 patients on CCT (> 5 days) who presented with ACS and received at least 1 DES were identified and were followed 
clinically up to 1 year. Of these 858 patients were reloaded with ≥ 300 mg of clopidogrel and 534 continued on maintenance dose. All patients 
continued CCT of 75 mg /day in addition to aspirin. Patients with cardiogenic shock and vein graft intervention were excluded.
Results: The baseline characteristics and the use of bivalirudin, heparin, and glycoprotein IIb/IIIa inhibitors were similar (see Table). The in-hospital 
and I year composite of major cardiac events (MACE) were similar without an increase in bleeding rate in both groups. However, there was an 
increase in stent thrombosis in patients who were not reloaded with clopidogrel (2.6% vs 0.4%, p=0.037)
Conclusions: Clopidogrel re-loading in patients with ACS subjected to PCI is safe, but does not impact in-hospital and one year clinical events.
Table 
Baseline Characteristics 
(n=1499)
No Re-Load
(n=547)
Re-Load
(n=952)
p value
Age (years) 65.01 +/- 11.88 62.84 +/- 12.51 0.001 
BMI 29.39 +/- 6.19 30.31 +/- 6.64 0.012 
African American 144/534 (27.0%) 287/858 (33.4%) 0.011
Diabetes Mellitus Type 2 224/531 (42.2%) 354/851 ( 41.6%) 0.830 
Smoker 98/534 (18.4%) 218/858 (25.4%) 0.002 
Number of diseased vessels 1.97 +/- 0.86 1.75 +/- 0.83 <.001 
Previous CABG 216/544 (39.7%) 317/947 (33.5%) 0.036 
Peripheral vascular disease 115/526 (21.9%) 141/855 (16.5%) 0.013 
Chronic renal insufficiency 109/534 (20.4%) 118/855 (13.8%) 0.001 
Myocardial infarction at presentation 106/533 (19.9%) 170/857 (19.8%) 0.982 
Procedural Characteristics
(Lesions =2401)
No Re-Load
(Lesions =945)
Re-Load
(Lesions=1456)
p value
Length of hospital stay, (days) 2.54 +/- 2.72 2.22 +/- 2.44 0.021 
Right Coronary PCI 307/945 (32.5%) 537/1456 (36.9%) 0.028 
Left Main PCI 31/945 (3.3%) 28/1456 (1.9%) 0.036 
Restenosis lesion 120/943 (12.7%) 153/1452 (10.5%) 0.100 
Bare metal stent 431/902 (47.8%) 1269/1433 (88.6%) <.001 
Pre-loaded with clopidogrel - 274/836 (32.8%) -
Post-loaded with clopidogrel - 667/844 (79.0%) -
Average pre-loading dose - 412.04 mg +/- 387.23 mg -
Average post-loading dose - 378.93 mg +/- 134.77 mg. -
In-Hospital outcomes
Major In-Hospital Complications (Death, QWMI, CABG) 4/534 (0.7%) 6/858 (0.7%) 1.000
In-hospital death 0.6% ( 3/534 0.6% ( 5/858 1.000
QWMI 0.0% ( 0/530 0.1% ( 1/857 1.000
CABG 0.2% ( 1/530 0.0% ( 0/855 0.383
Peri-procedural MI 195/ 527 (37.0%) 337/ 854 (39.5%) 0.362
Major Bleeding (GI bleeding, Hct drop > 15, Hematoma 
> 4cm)
0.9% ( 5/532 0.9% ( 8/858 1.000 
Subacute Stent Thrombosis 0/534 0/858 -
1 Year Outcomes
MACE (death,MI,TVR) 24.3% ( 66/272 19.9% ( 55/277 0.213
Cumulative stent thrombosis 2.6% ( 7/274 0.4% ( 1/278 0.037 
